Neurogene (NGNE) Net Income towards Common Stockholders (2013 - 2026)

Neurogene has reported Net Income towards Common Stockholders for 14 years, with the latest figure at -$31.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 36.9% year-over-year to -$31.1 million; the trailing twelve-month figure through Mar 2026 stood at -$100.1 million (down 23.67% YoY), and the FY2025 full-year result was -$91.8 million, down 23.78% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$31.1 million, down from -$24.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$11.7 million in Q4 2022, with the low at -$31.1 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$18.0 million across 5 years, with a median of -$16.5 million in 2024.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders rose 25.3% — and 2024, when it slumped 57.15%.
• Neurogene's Net Income towards Common Stockholders stood at -$11.7 million in 2022, then slipped by 19.69% to -$14.0 million in 2023, then slumped by 37.76% to -$19.2 million in 2024, then dropped by 28.17% to -$24.7 million in 2025, then dropped by 26.08% to -$31.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$31.1 million (Q1 2026), -$24.7 million (Q4 2025), and -$21.1 million (Q3 2025), per Business Quant data.